Voriconazole Clinical Trials

Size	Price	Qty
10mg	USD 147
100mg	USD 390

Clinical Trials

Numerous clinical trials evaluate voriconazole across Phase 1 through Phase 4—as well as pharmacokinetic, safety, and drug-interaction studies in healthy adults and pediatric patients with haematological malignancies—focusing on fungal infections such as chronic pulmonary aspergillosis, candidemia, invasive candidiasis, scedosporium infection, and blastomycosis. Conducted by both pharmaceutical sponsors and academic institutions, these studies encompass completed, active not recruiting, and terminated recruitment statuses.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06582186	NOT_YET_RECRUITING	Aspergillosis Invasive; Fungal Infection; Hematologic Malignancy	University Hospital, Grenoble	2024-10	PHASE4
NCT07215273	RECRUITING	Invasive Mould Infection	Elion Therapeutics, Inc.	2026-02-13	PHASE2
NCT07156201	RECRUITING	KCNT1-Related Epilepsy	Actio Biosciences, Inc.	2025-08-28	PHASE1
NCT06510699	RECRUITING	Fungal Infection; Haematological Malignancy; Blood Cancer; Infectious Disease	The University of Queensland	2025-04-14	PHASE2
NCT07457203	NOT_YET_RECRUITING	Drug Drug Interaction (DDI)	Beijing Union Pharmaceutical Factory Ltd	2026-04	PHASE1
NCT07426042	NOT_YET_RECRUITING	Drug-Drug Interactions	Min Kyu Park	2026-04	PHASE1
NCT06680544	NOT_YET_RECRUITING	Dermatophyte Infection	Sheikh Zayed Medical College	2024-11-15	PHASE2
NCT06493409	COMPLETED	Healthy Volunteers	Bristol-Myers Squibb	2024-08-26	PHASE1
NCT04294641	COMPLETED	Chronic GVHD	National Cancer Institute (NCI)	2021-05-10	PHASE2
NCT04824417	COMPLETED	Chronic Pulmonary Aspergillosis	Post Graduate Institute of Medical Education and Research, Chandigarh	2021-03-01	PHASE3
NCT05268718	UNKNOWN	Keratitis, Ulcerative; Antibiotic Resistance, Microbial; Photothermal Therapy	Second Affiliated Hospital, Zhejiang University, School of Medicine	2021-08-01	EARLY_PHASE1
NCT05708625	UNKNOWN	Leishmaniasis, Cutaneous	Zagazig University	2022-01-01	PHASE3
NCT04865419	TERMINATED	Haematological Malignancies	AstraZeneca	2021-06-11	PHASE1
NCT05458102	TERMINATED	Human Immunodeficiency Virus Type 1 (HIV-1) Infection	Gilead Sciences	2022-08-19	PHASE1
NCT05264142	UNKNOWN	Healthy	University Hospital, Geneva	2022-04-01	PHASE1
NCT03672292	TERMINATED	Invasive Pulmonary Aspergillosis	Scynexis, Inc.	2019-01-22	PHASE2
NCT07773909	COMPLETED	Acute Myeloid Leukemia	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	2022-06-01	PHASE4
NCT04072640	UNKNOWN	Cryptococcal Meningitis; HIV/AIDS	First Affiliated Hospital of Zhejiang University	2021-01-25	EARLY_PHASE1
NCT04551963	COMPLETED	B-cell Malignancies	BeiGene	2020-11-15	PHASE1
NCT03827278	UNKNOWN	Talaromyces in Human Immunodeficiency Virus Negative; To Compare Voriconazole and Amphotericin Sequential Itraconazole Therapy; To Dynamically Monitor the Anti-Interferon-γ Autoantibodies	Guangxi Medical University	2018-12-30
NCT04576325	COMPLETED	Asthma	TFF Pharmaceuticals, Inc.	2020-11-15	PHASE1
NCT04865419	Terminated	Haematological Malignancies	AstraZeneca	2021-06-11	Phase 1\|Phase 2
NCT03471988	COMPLETED	Deep Mycosis	Asahi Kasei Therapeutics Corporation	2018-04-16	PHASE3
NCT04824417	Active not recruiting	Chronic Pulmonary Aspergillosis	Post Graduate Institute of Medical Education and Research Chandigarh\|PGIMER	2021-03-01	Phase 3
NCT02283905	TERMINATED	Blastomycosis	University of Manitoba	2015-06	PHASE4
NCT04229303	COMPLETED	Allergic Bronchopulmonary Aspergillosis	Zambon SpA	2020-02-11	PHASE1
NCT04872231	COMPLETED	Healthy	TFF Pharmaceuticals, Inc.	2019-11-22	PHASE1
NCT05330000	COMPLETED	Healthy Adults	The Affiliated Hospital of Qingdao University	2020-05-22	PHASE1
NCT04552353	COMPLETED	Antimycotic for Systematic Use	Yung Shin Pharm. Ind. Co., Ltd.	2020-06-13	PHASE4
NCT03613389	UNKNOWN	Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy	Cairo University	2020-01-01
NCT04229303	Completed	Allergic Bronchopulmonary Aspergillosis	Zambon SpA	2020-02-11	Phase 1
NCT04238884	UNKNOWN	Invasive Fungal Infections	Instituto de Investigación Hospital Universitario La Paz	2020-01-02	PHASE4
NCT04145583	COMPLETED	Anesthesia; Sedation	Sichuan Haisco Pharmaceutical Group Co., Ltd	2019-12-14	PHASE1
NCT01503515	COMPLETED	Fungal Infection; Hematopoietic and Lymphoid Cell Neoplasm	Children's Oncology Group	2013-03-21	PHASE3
NCT04743544	Unknown status	Adverse Drug Reactions	Dokuz Eylul University\|University of Liverpool	2019-11-01	--
NCT03731169	COMPLETED	Aspergillosis Invasive; Fungal Infection	University Health Network, Toronto	2018-01-10	PHASE4
NCT01782131	COMPLETED	Fungal Infections; Invasive Pulmonary Aspergillosis	Merck Sharp & Dohme LLC	2013-09-25	PHASE3
NCT03327727	TERMINATED	Invasive Aspergillosis; Invasive Pulmonary Aspergillosis	Vical	2018-02-20	PHASE2
NCT03799809	UNKNOWN	Aspergilloma	All India Institute of Medical Sciences	2016-12-01	PHASE2; PHASE3
NCT05380245	COMPLETED	Healthy	Abdul Wali Khan University Mardan	2018-11-01	PHASE4
NCT02689713	WITHDRAWN	Pain; Thermal Injury; Burns; Hyperalgesia	Kenneth Hargreaves	2018-06-15	PHASE2
NCT03760276	COMPLETED	Fungal Infection	Seoul National University Hospital	2018-08-20	PHASE1
NCT02731638	COMPLETED	Corneal Ulcer; Fungal Keratitis	University of California, San Francisco	2016-09	PHASE3
NCT04110860	COMPLETED	Tinea Versicolor	Sara Botros	2018-02-15	PHASE2
NCT03515382	COMPLETED	Healthy	Lakefront Biotherapeutics NV	2018-03-16	PHASE1
NCT01950507	TERMINATED	Stem Cell Transplantation; Graft vs Host Disease	National Institutes of Health Clinical Center (CC)	2014-02-20	PHASE1
NCT03230058	UNKNOWN	Infection, Fungal	L.V. Prasad Eye Institute	2017-01-01	PHASE2; PHASE3
NCT02180165	COMPLETED	Aspergillosis	Merck Sharp & Dohme LLC	2014-07-29	PHASE3
NCT02227797	COMPLETED	Fungal Infection	Masonic Cancer Center, University of Minnesota	2015-01-19	PHASE1
NCT02014558	COMPLETED	Acute Myeloid Leukemia	Astellas Pharma Global Development, Inc.	2013-10-09	PHASE1; PHASE2
NCT03554239	WITHDRAWN	Infection	University Hospital, Toulouse	2016-12
NCT03138785	UNKNOWN	Treatment	Farabi Eye Hospital	2015-01-01
NCT02576366	COMPLETED	Drug Interactions; Kidney Transplantation	Universitaire Ziekenhuizen KU Leuven	2016-06	PHASE4
NCT02396225	TERMINATED	Invasive Aspergillosis	University of Aarhus	2015-03
NCT01887457	SUSPENDED	Immunocompromised Patient; Aspergillosis; Fusarium	Brynn Chappell	2014-09	PHASE2
NCT02906176	COMPLETED	Healthy Volunteers	Seoul National University Hospital	2016-09	PHASE1
NCT00893555	COMPLETED	Invasive Fungal Infection; Hematological Malignancy	Jan-Willem C Alffenaar	2009-04	PHASE3
NCT02234739	UNKNOWN	Invasive Pulmonary Aspergillosis; COPD	Red Cross Hospital, Hangzhou, China	2014-10	PHASE4
NCT02912156	COMPLETED	Fungus Infection	Yung Shin Pharm. Ind. Co., Ltd.	2016-06	PHASE4
NCT02381080	COMPLETED	B-Cell Chronic Lymphocytic Leukemia	Janssen Research & Development, LLC	2015-05-19	PHASE1
NCT02110316	WITHDRAWN	Voriconazole; Bioavailability; Critically Ill	University Medical Center Groningen	2015-06	PHASE4
NCT01621321	COMPLETED	Allergic Bronchopulmonary Aspergillosis	Post Graduate Institute of Medical Education and Research, Chandigarh	2013-06	PHASE2; PHASE3
NCT00997035	COMPLETED	Corneal Ulcer; Eye Infections, Fungal	University of California, San Francisco	2010-05	PHASE3
NCT02631954	COMPLETED	Aspergillus Infections; Candida Infections; Fungal Infections	Chong Kun Dang Pharmaceutical	2015-09	PHASE1
NCT01576315	COMPLETED	Cystic Fibrosis; Aspergillus Infections	Rennes University Hospital	2014-06	PHASE2
NCT00413218	COMPLETED	Candidiasis, Invasive; Candidemia; Mycoses	Astellas Pharma Inc	2007-03-08	PHASE3
NCT01416025	COMPLETED	Fungal Infection	Johns Hopkins University	2012-01	PHASE4
NCT02714504	COMPLETED	Fusariosis; Onychomycosis	Universidade Federal do Rio de Janeiro	2008-08
NCT01344512	COMPLETED	Pediatrics; Ceftazidime; Ciprofloxacin; Voriconazole	University Hospital, Bordeaux	2011-06
NCT01188759	WITHDRAWN	Aspergillosis; Invasive Pulmonary Aspergillosis; Neuroaspergillosis	Pfizer	2012-05	PHASE3
NCT01185405	WITHDRAWN	Invasive Fungal Infection	Asan Medical Center	2010-08
NCT01092832	TERMINATED	Candidiasis	Pfizer	2010-10	PHASE3
NCT01383993	COMPLETED	Aspergillosis, Aspergilloma	Pfizer	2011-09	PHASE2
NCT00836875	TERMINATED	Invasive Aspergillosis	Pfizer	2009-05	PHASE3
NCT01787032	COMPLETED	Healthy	Boehringer Ingelheim	2013-01	PHASE1
NCT00412893	COMPLETED	Aspergillosis; Invasive Fungal Infection	Astellas Pharma Inc	2007-03-07	PHASE3
NCT01539330	COMPLETED	Healthy	Martin-Luther-Universität Halle-Wittenberg	2009-02	PHASE4
NCT01657201	COMPLETED	Systemic Mycotic Infection	Samyang Biopharmaceuticals Corporation	2012-09	PHASE1
NCT00792246	COMPLETED	Graft Versus Host Disease; Stem Cell Transplantation	Phillip Brian Smith	2008-12	PHASE1
NCT00996736	COMPLETED	Corneal Ulcer; Eye Infections, Fungal	University of California, San Francisco	2010-04	PHASE3
NCT01207128	WITHDRAWN	Aspergillosis	University of Arkansas	2011-02	PHASE2
NCT01466803	COMPLETED	Healthy	Turku University Hospital	2011-10	PHASE1
NCT00890708	COMPLETED	Mycoses	Seoul National University Hospital	2008-11
NCT00353158	COMPLETED	Healthy Volunteers; Fungal Infections; Bacterial Infections	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	2007-05-25	PHASE1
NCT00531479	COMPLETED	Aspergillosis	Pfizer	2008-07	PHASE3
NCT01367808	COMPLETED	Pharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine	Turku University Hospital	2011-02	PHASE1
NCT01104376	COMPLETED	Efavirenz, Metabolism and Pharmacokinetics Changes	Indiana University	2010-03
NCT00904995	COMPLETED	Leukemia; Fungal Infection	M.D. Anderson Cancer Center	2009-05	PHASE3
NCT00833482	COMPLETED	Human Immunodeficiency Virus Type 1 (HIV-1); HIV Infections	Bristol-Myers Squibb	2009-09	PHASE1
NCT00496197	COMPLETED	Candidiasis	Pfizer	2007-07	PHASE4
NCT00689338	COMPLETED	Invasive Candidiasis	Pfizer	2008-07	PHASE3
NCT01030653	COMPLETED	Healthy	Manjunath Prakash Pai	2009-11	PHASE4
NCT00624143	UNKNOWN	Pediatric Acute Leukemia Induction	All India Institute of Medical Sciences	2008-02	PHASE3
NCT00556998	COMPLETED	Pharmacokinetics	Pfizer	2008-06	PHASE2
NCT00418951	COMPLETED	Acute Myelogenous Leukemia; Myelodysplastic Syndrome	M.D. Anderson Cancer Center	2006-11	PHASE2
NCT00548262	COMPLETED	Candidemia; Invasive Candidiasis	Pfizer	2008-02	PHASE4
NCT00739934	COMPLETED	Candidiasis; Candidemia	Pfizer	2008-12	PHASE2
NCT00855101	COMPLETED	Healthy Volunteers	Pfizer	2009-04	PHASE1
NCT00150345	COMPLETED	Possible Fungal Infection	Pfizer	2005-01	PHASE3
NCT00942773	COMPLETED	Healthy	Seoul National University Hospital	2008-12	PHASE1
NCT01080651	COMPLETED	Invasive Aspergillosis	Seoul National University Hospital	2008-12	PHASE1
NCT00289991	COMPLETED	Antifungal Prophylaxis of Invasive Fungal Infections	Pfizer	2006-03	PHASE3
NCT00620074	TERMINATED	Aspergillosis	Pfizer	2008-08	PHASE4
NCT00740389	COMPLETED	HIV; AIDS; Fungal Infection	Tibotec Pharmaceuticals, Ireland	2008-09	PHASE1
NCT00159822	COMPLETED	Aspergillosis	Pfizer	2005-07	PHASE2; PHASE3
NCT00386802	COMPLETED	Invader Fungal Infection	PETHEMA Foundation	2006-08	PHASE4
NCT00940017	COMPLETED	Aspergillosis; Candidemia	Pfizer	2008-09	PHASE4
NCT00557362	COMPLETED	Fungal Keratitis	University of California, San Francisco	2007-11	PHASE1; PHASE2
NCT00300677	COMPLETED	Infections, Fungal	Pfizer	2007-03	PHASE4
NCT00238355	TERMINATED	Infection; Unspecified Adult Solid Tumor, Protocol Specific	OHSU Knight Cancer Institute	2003-08	PHASE2
NCT00143312	COMPLETED	Prophylaxis Of Invasive Fungal Infections	Pfizer	2005-02	PHASE4
NCT00288197	COMPLETED	Invasive Fungal Infections	Pfizer	2006-01	PHASE4
NCT00455364	TERMINATED	Infection	University of Chicago	2007-04	PHASE4
NCT00075803	COMPLETED	Lymphoma; Infection; Leukemia	Medical College of Wisconsin	2003-11	PHASE3
NCT00079222	COMPLETED	Cancer	Jonsson Comprehensive Cancer Center	2003-11
NCT00003031	COMPLETED	Infection; Pulmonary Complications	European Organisation for Research and Treatment of Cancer - EORTC	1997-06	PHASE3
NCT00059878	COMPLETED	Infection; Unspecified Adult Solid Tumor, Protocol Specific	National Cancer Institute (NCI)	2003-08	PHASE2
NCT00001810	COMPLETED	Aspergillosis; Candidiasis; Fungemia; Mycoses	National Cancer Institute (NCI)	1999-04	PHASE3
NCT00163111	COMPLETED	Candidiasis	Pfizer	1998-09	PHASE3
NCT00015665	COMPLETED	Mycoses	National Institute of Allergy and Infectious Diseases (NIAID)	2001-04	PHASE3
NCT00647907	COMPLETED	Candidiasis; Cryptococcosis; Aspergillosis	Pfizer	2003-04	PHASE4
NCT00005912	COMPLETED	Aspergillosis; Candidiasis; Fungal Diseases; Mycoses	National Cancer Institute (NCI)	2000-06	PHASE1
NCT00152594	TERMINATED	Leukemia, Myelocytic, Acute	University of Cologne	2004-10	PHASE3
NCT00001940	COMPLETED	Mycoses	National Cancer Institute (NCI)	1999-12	PHASE3
NCT00174473	COMPLETED	Neutropenia	Pfizer	2003-06	PHASE1; PHASE2
NCT00023530	COMPLETED	Bone Marrow Transplantation; Blood Disease; Hematopoietic Stem Cell Transplantation; Leukemia; Multiple Myeloma; Myelodysplastic Syndromes; Graft vs Host Disease	National Heart, Lung, and Blood Institute (NHLBI)	2001-09
NCT00066599	COMPLETED	Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Neuroblastoma; Neutropenia; Sarcoma	National Cancer Institute (NCI)	2003-06	PHASE2
NCT00001757	COMPLETED	Mycoses	National Institute of Allergy and Infectious Diseases (NIAID)	1997-11	PHASE3
NCT00423163	WITHDRAWN	Aspergillosis/Blood; Aspergillosis/Invasive	Astellas Pharma Inc	2007-02	PHASE4
NCT00001646	COMPLETED	Acquired Immunodeficiency Syndrome; Aspergillosis; HIV Infections; Immunologic Deficiency Syndromes; Neutropenia	National Institute of Allergy and Infectious Diseases (NIAID)	1997-08	PHASE3
NCT00136968	COMPLETED	Fungal Infection	Pfizer	2005-04	PHASE1

(data from https://clinicaltrials.gov, updated on 2024-09-03)

Check the Voriconazole product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Voriconazole selectively binds to fungal cytochrome P450-dependent 14-alpha-sterol demethylase, inhibiting the conversion of lanosterol to ergosterol and causing the accumulation of toxic 14-alpha-methyl sterols that compromise fungal cell membrane integrity and inhibit fungal cell growth. This disruption of cell membrane synthesis produces potent antifungal activity against pathogenic fungal species, providing the molecular basis for its clinical efficacy in managing invasive candidiasis and chronic pulmonary aspergillosis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).